Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2017

Open Access 01-12-2017 | Research article

Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ

Authors: Chae-Lyul Lim, Yeon-Ju Lee, Jong-Ho Cho, Heonsik Choi, Bumsup Lee, Myung Chul Lee, Sujeong Kim

Published in: BMC Musculoskeletal Disorders | Issue 1/2017

Login to get access

Abstract

Background

Invossa™ (TissueGene-C) is a cell and gene therapy for osteoarthritis. It is composed of primary human chondrocytes (hChonJ cells) and irradiated human chondrocytes modified to express TGF-β1 (hChonJb#7 cells). The hChonJ cells were isolated from a polydactyly donor, and TGF-β1 cDNA was delivered to the cells, generating hChonJb#7 cells. Since the cells are allogeneic, the concern of immune response against cells has been raised. In this study, we investigated the immunogenicity of allogenic human chondrocyte, hChonJ cells.

Methods

The immunological properties of hChonJ cells were investigated through the analysis of surface marker expression and the effect on allogeneic T cell proliferation. Flow cytometry and RT-PCR analysis were performed to analyze the surface marker expression related to immune response, such as major histocompatibility complex (MHC) class I, class II, T cell co-stimulatory molecules and T cell co-inhibitory molecules. A mixed lymphocyte reaction (MLR) was conducted to evaluate how allogeneic T cells would respond to hChonJ cells.

Results

We observed that hChonJ cells did not express MHC class II and T cell co-stimulatory molecules, but expressed T cell co-inhibitory molecule PD-L2. IFN-γ treatment induced the expression of PD-L1, and up-regulated the expression of PD-L2. Also, we observed that hChonJ cells did not stimulate T cell proliferation from a MHC-mismatched donor. Further, they could suppress the proliferation of activated T cells. We also observed that the blockade of PD-L1 and/or PD-L2 with specific neutralizing antibody could lead to the restoration of allo-reactive T cell proliferation.

Conclusions

We showed that hChonJ cells were not immunogenic but immunosuppressive, and that this phenomenon was mediated by co-inhibitory molecules PD-L1 and PD-L2 on hChonJ cells in a contact-dependent manner.
Appendix
Available only for authorised users
Literature
1.
go back to reference Elmallah RK, Cherian JJ, Jauregui JJ, et al. Genetically modified chondrocytes expressing TGF-β1: a revolutionary treatment for articular cartilage damage? Expert Opin Biol Ther. 2015;15:455.CrossRefPubMed Elmallah RK, Cherian JJ, Jauregui JJ, et al. Genetically modified chondrocytes expressing TGF-β1: a revolutionary treatment for articular cartilage damage? Expert Opin Biol Ther. 2015;15:455.CrossRefPubMed
3.
go back to reference Cucchiarini M and Madry H. Gene Therapy for Human Osteoarthritis. Osteoarthritis - Diagnosis, Treatment and Surgery, Prof. Qian Chen (Ed.), 2012, ISBN: 978-953-51-0168-0 Cucchiarini M and Madry H. Gene Therapy for Human Osteoarthritis. Osteoarthritis - Diagnosis, Treatment and Surgery, Prof. Qian Chen (Ed.), 2012, ISBN: 978-953-51-0168-0
4.
go back to reference Song SU, Cha YD, Han JU, et al. Hyaline cartilage regeneration using mixed human chondrocytes and transforming growth factor-beta1-producing chondrocytes. Tissue Eng. 2005;11:1516.CrossRefPubMed Song SU, Cha YD, Han JU, et al. Hyaline cartilage regeneration using mixed human chondrocytes and transforming growth factor-beta1-producing chondrocytes. Tissue Eng. 2005;11:1516.CrossRefPubMed
5.
go back to reference Noh MJ, Copeland RO, Yi Y, et al. Pre-clinical studies of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 (TG-C). Cytotherapy. 2010;12:384.CrossRefPubMed Noh MJ, Copeland RO, Yi Y, et al. Pre-clinical studies of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 (TG-C). Cytotherapy. 2010;12:384.CrossRefPubMed
6.
go back to reference Lee DK, Choi KB, Oh IS, et al. Continuous transforming growth factor beta1 secretion by cell-mediated gene therapy maintains chondrocyte redifferentiation. Tissue Eng. 2005;11:310.CrossRefPubMed Lee DK, Choi KB, Oh IS, et al. Continuous transforming growth factor beta1 secretion by cell-mediated gene therapy maintains chondrocyte redifferentiation. Tissue Eng. 2005;11:310.CrossRefPubMed
7.
go back to reference Ha CW, Noh MJ, Choi KB, Lee KH. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy. 2012;14:247.CrossRefPubMedCentralPubMed Ha CW, Noh MJ, Choi KB, Lee KH. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy. 2012;14:247.CrossRefPubMedCentralPubMed
8.
go back to reference Ha CW, Cho JJ, Elmallah RK, et al. A multicenter, single-blind, phase IIa clinical trial to evaluate the efficacy and safety of a cell mediated gene therapy in degenerative knee arthritis patients. Hum Gene Ther Clin Dev. 2015;26:125.CrossRefPubMed Ha CW, Cho JJ, Elmallah RK, et al. A multicenter, single-blind, phase IIa clinical trial to evaluate the efficacy and safety of a cell mediated gene therapy in degenerative knee arthritis patients. Hum Gene Ther Clin Dev. 2015;26:125.CrossRefPubMed
9.
go back to reference Lee MC, Ha CW, Elmallah RD, et al. A placebo-controlled randomised trial to assess the effect of TGF-ß1-expressing chondrocytes in patients with arthritis of the knee. Bone Joint J. 2015;97:924.CrossRefPubMed Lee MC, Ha CW, Elmallah RD, et al. A placebo-controlled randomised trial to assess the effect of TGF-ß1-expressing chondrocytes in patients with arthritis of the knee. Bone Joint J. 2015;97:924.CrossRefPubMed
10.
go back to reference Cherian JJ, Parvizi J, Bramlet D, Lee KH, Romness DW, Mont MA. Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee. Osteoarthritis Cartilage. 2015;23(12):2109.CrossRefPubMed Cherian JJ, Parvizi J, Bramlet D, Lee KH, Romness DW, Mont MA. Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee. Osteoarthritis Cartilage. 2015;23(12):2109.CrossRefPubMed
11.
go back to reference Gross AE, Shasha N, Aubin P. Long-term follow up of the use of fresh osteochondral allografts for posttraumatic knee defects. Clin Orthop Relat Res. 2005;435:79.CrossRef Gross AE, Shasha N, Aubin P. Long-term follow up of the use of fresh osteochondral allografts for posttraumatic knee defects. Clin Orthop Relat Res. 2005;435:79.CrossRef
12.
go back to reference Bugbee WD. Fresh osteochondral allografts. J Knee Surg. 2002;15:191.PubMed Bugbee WD. Fresh osteochondral allografts. J Knee Surg. 2002;15:191.PubMed
13.
go back to reference Langer F, Gross AE. Immunogenicity of allograft articular cartilage. J Bone Joint Surg Am. 1974;56:297.CrossRefPubMed Langer F, Gross AE. Immunogenicity of allograft articular cartilage. J Bone Joint Surg Am. 1974;56:297.CrossRefPubMed
14.
15.
go back to reference Feder J, Adkisson HD, Kizer N, et al. The promise of chondral repair using neocartilage. In: Sandell LJ, Grodzinsky AJ, editors. Tissue engineering in musculoskeletal clinical practice. 1st ed. Rosemont: American Academy of Orthopedic Surgeons; 2004. p. 219. Feder J, Adkisson HD, Kizer N, et al. The promise of chondral repair using neocartilage. In: Sandell LJ, Grodzinsky AJ, editors. Tissue engineering in musculoskeletal clinical practice. 1st ed. Rosemont: American Academy of Orthopedic Surgeons; 2004. p. 219.
16.
go back to reference Lu Y, Adkisson HD, Bogdanske J, et al. In vivo transplantation of neonatal ovine neocartilage allografts: determining the effectiveness of tissue transglutaminase. J Knee Surg. 2005;18:31.PubMed Lu Y, Adkisson HD, Bogdanske J, et al. In vivo transplantation of neonatal ovine neocartilage allografts: determining the effectiveness of tissue transglutaminase. J Knee Surg. 2005;18:31.PubMed
17.
go back to reference Adkisson HD, Milliman C, Zhang X, et al. Immune evasion by neocartilage-derived chondrocytes: Implications for biologic repair of joint articular cartilage. Stem Cell Res. 2010;4:57.CrossRefPubMed Adkisson HD, Milliman C, Zhang X, et al. Immune evasion by neocartilage-derived chondrocytes: Implications for biologic repair of joint articular cartilage. Stem Cell Res. 2010;4:57.CrossRefPubMed
18.
go back to reference del Rio ML, Buhler L, Gibbons C, et al. PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl Int. 2008;21:1015.PubMed del Rio ML, Buhler L, Gibbons C, et al. PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl Int. 2008;21:1015.PubMed
19.
go back to reference Mellor A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun. 2005;338:20.CrossRefPubMed Mellor A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun. 2005;338:20.CrossRefPubMed
20.
go back to reference Wingender G, Garbi N, Schumak B, et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol. 2006;36:12.CrossRefPubMed Wingender G, Garbi N, Schumak B, et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol. 2006;36:12.CrossRefPubMed
21.
go back to reference Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762.CrossRefPubMed Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762.CrossRefPubMed
22.
go back to reference Vlad SC, Neogi T, Aliabadi P, et al. No association between markers of inflammation and osteoarthritis of the hands and knees. J Rheumatol. 2011;38:1665.CrossRefPubMedCentralPubMed Vlad SC, Neogi T, Aliabadi P, et al. No association between markers of inflammation and osteoarthritis of the hands and knees. J Rheumatol. 2011;38:1665.CrossRefPubMedCentralPubMed
23.
go back to reference Sakkas LI, Platsoucas CD. The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheum. 2007;56:409.CrossRefPubMed Sakkas LI, Platsoucas CD. The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheum. 2007;56:409.CrossRefPubMed
24.
go back to reference Nakamura H, Yoshino S, Kato T, et al. T-cell mediated inflammatory pathway in osteoarthritis. Osteoarthritis Cartilage. 1999;7:401.CrossRefPubMed Nakamura H, Yoshino S, Kato T, et al. T-cell mediated inflammatory pathway in osteoarthritis. Osteoarthritis Cartilage. 1999;7:401.CrossRefPubMed
25.
go back to reference Shen PC, Wu CL, Jou IM, et al. T helper cells promote disease progression of osteoarthritis by inducing macrophage inflammatory protein-1γ. Osteoarthritis Cartilage. 2011;19:728.CrossRefPubMed Shen PC, Wu CL, Jou IM, et al. T helper cells promote disease progression of osteoarthritis by inducing macrophage inflammatory protein-1γ. Osteoarthritis Cartilage. 2011;19:728.CrossRefPubMed
26.
go back to reference Rodig N, Ryan T, Allen JA, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003;33:3117.CrossRefPubMed Rodig N, Ryan T, Allen JA, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003;33:3117.CrossRefPubMed
27.
go back to reference Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169:5538.CrossRefPubMed Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169:5538.CrossRefPubMed
28.
go back to reference Nakazawa A, Dotan I, Brimnes J, et al. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology. 2004;126:1347.CrossRefPubMed Nakazawa A, Dotan I, Brimnes J, et al. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology. 2004;126:1347.CrossRefPubMed
30.
go back to reference Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261.CrossRefPubMed Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261.CrossRefPubMed
31.
32.
go back to reference Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191.CrossRefPubMed Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191.CrossRefPubMed
33.
go back to reference Hwu P, Du MX, Lapointe R, et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. 2000;164:3596.CrossRefPubMed Hwu P, Du MX, Lapointe R, et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. 2000;164:3596.CrossRefPubMed
34.
go back to reference Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619.CrossRefPubMed Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619.CrossRefPubMed
Metadata
Title
Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ
Authors
Chae-Lyul Lim
Yeon-Ju Lee
Jong-Ho Cho
Heonsik Choi
Bumsup Lee
Myung Chul Lee
Sujeong Kim
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2017
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-017-1547-8

Other articles of this Issue 1/2017

BMC Musculoskeletal Disorders 1/2017 Go to the issue